Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: GlobeNewswire
NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN). The investigation concerns whether Regeneron and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more about the investigation] On April 10, 2024, the U.S. Department of Justice (“DOJ”) issued a press release announcing its complaint filed against Regeneron under the False Claims Act. The lawsuit accuses the Company of failing to report millions of dollars in discounts provided to drug distributors. As a result, the DOJ alleges that the average selling price of Regeneron’s Eylea drug was inflated above the amount allowed by Medicare. On this news, the price of Regeneron shares declined by $31.50 per share, or approximately 3.36%, over two consecutive trading days to close at $904.70 on Apri
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- Adverum Biotechnologies a new buy at H.C. Wainwright on wet AMD gene therapy [Seeking Alpha]Seeking Alpha
- Roche's VABYSMO has successful Q1 sales despite Regeneron and Bayer's EYLEA HD launch [Yahoo! Finance]Yahoo! Finance
- INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire
- REGN4461 (Mibavademab) for Lipodystrophy in 7MM: Market Size, Sales, Forecasts, and Emerging Insights 2019-2023, 2024-2032 [Yahoo! Finance]Yahoo! Finance
- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
REGN
Earnings
- 2/2/24 - Beat
REGN
Sec Filings
- 5/1/24 - Form 4
- 5/1/24 - Form 4
- 4/25/24 - Form ARS
- REGN's page on the SEC website